October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart ...

Pauline M. Maki, PhD, discusses how the boxed-warning removal for hormone therapy and an expanding class of neurokinin-targeted therapies broaden options, and shares her key takeaway from OPTION-VMS.

Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.

Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, ...

Sleep disturbance is often the most bothersome symptom of the menopause transition, yet it frequently goes unreported unless ...

Cheryl Cox Kinney, MD, identifies VMS red flags that warrant further evaluation, including fever, weight loss, ...

Approximately 21% of women initiated systemic HT after menopause, with substantial declines in treatment persistence during ...

JoAnn Pinkerton, MD, discusses elinzanetant's onset of VMS relief, common adverse effects, and treatment expectations for ...

Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and ...

Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, ...

Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in ...

Only 21.7% of more than 318 000 women initiated systemic hormone therapy (HT) within 12 months of a natural menopause ...